Claims
- 1. A purified and isolated or recombinantly produced compound having the formula:
- 2. The compound of claim 1 which has one or more characteristics selected from the group consisting of:
the C-terminal carboxyl is of the formula selected from the group consisting of COOH or salts thereof; COOR, CONH2, CONHR and CONR2 wherein each R is independently a hydrocarbyl (1-6C); the amino group at the N-terminus is of the formula NH2 or NHCOR wherein R is a hydrocarbyl (1-6C); each of A1 and A9 is independently selected from the group consisting of R, K and Har; each of A2 and A3 is independently selected from the group consisting of G, A, S and T; A4 is R or G; each of A5, A14, and A16 is independently selected from the group consisting of I, V, NLe, L and F; each of A7 and A12 is independently selected from the group consisting of I, V, L, W, Y and F; A10 is R, G or P; and A11 is R or W.
- 3. The compound of claim 1 which has antimicrobial or antiviral activity against pathogens associated with sexually transmitted disease.
- 4. The compound of claim 1 which has antimicrobial or antiviral activity against Escherichia coli, Listeria monocytogenes, Candida albicans, Pseudomonas aeruginosa, Kiebsiella pneumoniae, Salmonella typhimurium, Staphylococcus aureus, Histoplasma capsulatum, Myobacterium aviumintracellulare, Mycobacterium tuberculosis, Vibrio vulnificus, Chlamydia trachomatis, Treponema pallidum, Neisseria gonorrhoeae, Trichomonas vaginalis, Herpes simplex virus type 1, Herpes simplex virus type 2, human immunodeficiency virus, Hemophilus ducreyi, or human papilloma virus.
- 5. The compound of claim 1 which is selected from the group consisting of
- 6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.
- 7. A method of inhibiting the growth of a microbe or the replication of a virus which comprises the step of contacting said virus or said microbe with an amount of a compound according to claim 1 effective to inhibit said growth or said replication.
- 8. The method of claim 7 in which the microbe is a bacteria.
- 9. The method of claim 7 in which the microbe or virus is a sexually-transmitted microbe or virus.
- 10. The method of claim 9 in which the sexually-transmitted microbe or virus is selected from the group consisting of HIV-1, Chlamydia trachomatis, Treponema pallidum, Neisseria gonorrhoeae, Trichonomis vaginalis, HSV-1, HSV-2, Hemophilus ducreyi and human papilloma virus
- 11. The method of claim 7 in which the microbe or virus is HIV.
- 12. The method of claim 7 in which the microbe or virus is methicillin-resistant S. aureus (MRSA) or vancomycin-resistant E. faecalis (VREF).
- 13. A method to treat or prevent a microbial or viral infection in a subject, which method comprises administering to a subject in need of such treatment an amount of a compound according to claim 1 effective to ameliorate or prevent said infection in the subject.
- 14. The method of claim 13 in which the infection is a bacterial infection.
- 15. The method of claim 14 in which the bacteria is selected from the group consisting of E. Coli, L. monocytogenes, B. subtilis, S. typhimurium, S. aureus and P. aeruginosa.
- 16. The method of claim 13 in which the infection is caused by a sexually-transmitted pathogen.
- 17. The method of claim 16 in which the sexually-transmitted pathogen is selected from the group consisting of HIV-1, Chlamydia trachomatis, Treponema pallidum, Neisseria gonorrhoeae, Trichonomis vaginalis, HSV-1, HSV-2, Hemophilus ducreyi and human papilloma virus.
- 18. The method of claim 13 in which the infection is an HIV infection.
- 19. The method of claim 13 in which the infection is a methicillin-resistant S. aureus (MRSA) or vancomycin-resistant E. faecalis (VREF) infection.
- 20. The method of claim 13 in which the compound is administered topically.
- 21. The method of claim 13 in which the compound is administered prophylactically.
Parent Case Info
[0001] This application is a continuation of application Ser. No. 08/499,523, filed Jul. 7, 1995, which is a continuation-in-part of U.S. Ser. No. 08/451,832, filed May 26, 1995, which is a continuation-in-part of U.S. Ser. No. 08/243,879 filed May 17, 1994, which is a continuation-in-part of U.S. Ser. No. 08/182,483 filed Jan. 13, 1994, which is a continuation-in-part of U.S. Ser. No. 08/095,769 filed Jul. 26, 1993, which is a continuation-in-part of U.S. Ser. No. 08/093,926 filed Jul. 20, 1993. The contents of these applications are incorporated herein by reference.
Government Interests
[0002] This invention was made with funding from NIH Grant No. A122839. The U.S. Government has certain rights in this invention.
Divisions (6)
|
Number |
Date |
Country |
Parent |
08499523 |
Jul 1995 |
US |
Child |
09128345 |
Aug 1998 |
US |
Parent |
08451832 |
May 1995 |
US |
Child |
09128345 |
Aug 1998 |
US |
Parent |
08243879 |
May 1994 |
US |
Child |
09128345 |
Aug 1998 |
US |
Parent |
08182483 |
Jan 1994 |
US |
Child |
09128345 |
Aug 1998 |
US |
Parent |
08095769 |
Jul 1993 |
US |
Child |
09128345 |
Aug 1998 |
US |
Parent |
08093926 |
Jul 1993 |
US |
Child |
09128345 |
Aug 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09128345 |
Aug 1998 |
US |
Child |
09539443 |
Mar 2000 |
US |